Amplify Weight Loss Drug & Treatment ETF

THNR

Market cap $3.08M

The U.S. Food and Drug Administration's recent enforcement action against drug promotion is sending ETFs with exposure to weight-loss treatment manufacturers into question.

Amplify Weight Loss Drug & Treatment ETF THNR is probably on the radar for investors seeking momentum. The fund just hit a 52-week high and moved up 51.9% from its 52-week low price of $18.56/share.

For many of us, a new year often means a new chance to start fresh in our battle with weight. Thanks to interesting ETF product development, especially in the past year, it could also mean a chance to consider the investment opportunity in weight loss as a theme.

2024 was an amazing year for investment performance, with the broad market S&P 500 TR Index up over 28%. There were also some serious ETF milestones achieved this year.

Medical breakthroughs are occurring constantly, but they often get lost in the news headlines unless they directly impact our lives. I wanted to take a moment to highlight a few recent medical breakthroughs and developments and explore a few ways to get actionable exposure to them with ETFs.

With the completion of a close presidential election, roughly half of us are likely disappointed regardless of the winner. To counter the post-election blues, I identified some “happy” ETF themes to consider for investment.

As the ETF landscape continues to expand, more and more firms are crossing over significant AUM thresholds. That includes some now-veteran shops with strong, growing rosters, like Amplify ETFs.

Investors seeking to tap the boom in weight-loss drug treatment could consider these ETFs.

When markets correct, it is a good time to revisit which equity market sectors are “defensive” themes. Certain products and services are nondiscretionary in nature that we cannot live without.

Two companies, Eli Lilly (LLY) and Novo Nordisk (NVO), have so far dominated the weight-loss drug market. Now, Roche recently announced encouraging Phase I trial data for its new obesity drug candidate.